Skip to main content

29.10.2019 | Case Report | Ausgabe 2/2020

Pediatric Cardiology 2/2020

Intravenous Sotalol for the Treatment of Ventricular Dysrhythmias in an Infant on Extracorporeal Membrane Oxygenation

Pediatric Cardiology > Ausgabe 2/2020
Jessica L. Jacobson, John C. Somberg, Hoang H. Nguyen
Wichtige Hinweise

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.


Sotalol is a class III anti-arrhythmic agent with beta receptor blocking properties. Intravenous (IV) sotalol may be useful to treat refractory atrial and ventricular arrhythmias. A report on the efficacy and safety of IV sotalol in an infant on extracorporeal membrane oxygenation (ECMO) and continuous renal replacement therapy (CRRT), who developed refractory ventricular arrhythmias following surgery for congenital heart disease. A 10-day old infant with severe pulmonary valve stenosis underwent surgical pulmonary valvectomy and enlargement of the main pulmonary artery. Post-operatively, the patient developed hemodynamically significant accelerated idioventricular rhythm which was not responsive to a combination of amiodarone, lidocaine, and procainamide leading to 2 cardiac arrest events and placement on ECMO. The amiodarone infusion was uptitrated to 20 mcg/kg/min, but episodes of the hemodynamically compromising arrhythmia continued. Amiodarone was discontinued and IV sotalol was initiated at 42 mg/m2/day, divided to 3 doses, and administered every 8 h, which completely suppressed the arrhythmia. The initial sotalol dose was calculated based on a daily dose of 90 mg/m2 and reduced by an age-related factor as recommended by the FDA approved prescribing information. Subsequently, acute kidney injury requiring CRRT developed. The patient remained on IV sotalol for 3 weeks and then transitioned to oral sotalol. The oral dose was increased to 44 mg/m2/day (3.5 mg every 8 h) to account for the difference in bioavailability between the IV and oral formulations. Serial sotalol levels during IV and PO therapy remained therapeutic on ECMO and CRRT. The patient maintained normal sinus rhythm on sotalol without adverse events. IV sotalol in the setting of ECMO and CRRT was safe and effective in controlling refractory hemodynamically compromising accelerated idioventricular rhythm unresponsive to amiodarone.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

e.Med Interdisziplinär

Für Ihren Erfolg in Klinik und Praxis - Die beste Hilfe in Ihrem Arbeitsalltag als Mediziner*in

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf

Jetzt e.Med zum Sonderpreis bestellen!
Das Angebot gilt nur bis 24.10.2021

Weitere Produktempfehlungen anzeigen
Über diesen Artikel

Weitere Artikel der Ausgabe 2/2020

Pediatric Cardiology 2/2020 Zur Ausgabe
  1. Sie können e.Med Pädiatrie 14 Tage kostenlos testen (keine Print-Zeitschrift enthalten). Der Test läuft automatisch und formlos aus. Es kann nur einmal getestet werden.

Neu im Fachgebiet Kardiologie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Kardiologie und bleiben Sie gut informiert – ganz bequem per eMail.